Homidium

Homidium

SCHEMBL29391335

CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 1.00
KMT2A Q03164 5/20 1.00
MAPT P10636 5/20 1.00
BLM P54132 4/20 1.00
KDM4E B2RXH2 4/20 1.00
HPGD P15428 4/20 1.00
HTT P42858 4/20 1.00
CYP3A4 P08684 3/20 1.00
THRB P10828 3/20 1.00
CASP1 P29466 3/20 1.00
RECQL P46063 3/20 1.00
CASP7 P55210 3/20 1.00
TERT O14746 3/20 1.00
ALDH1A1 P00352 3/20 1.00
MAPK1 P28482 3/20 1.00
HSD17B10 Q99714 3/20 1.00
MITF O75030 2/20 1.00
NSD2 O96028 2/20 1.00
LMNA P02545 2/20 1.00
TP53 P04637 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Homidium SCHEMBL27609 1.00 MEN1 (1.00) MEN1KMT2AMAPTBLMKDM4E
Homidium SCHEMBL21647365 1.00 MEN1 (1.00) MEN1KMT2AMAPTBLMKDM4E
Homidium SCHEMBL31511751 1.00 MEN1 (1.00) MEN1KMT2AMAPTBLMKDM4E
Homidium SCHEMBL612343 0.99 MEN1 (0.97) MEN1KMT2AMAPTBLMKDM4E
Homidium SCHEMBL11023665 0.99 MEN1 (0.97) MEN1KMT2AMAPTBLMKDM4E
Homidium SCHEMBL3025214 0.99 MEN1 (1.00) MEN1KMT2AMAPTBLMKDM4E
Homidium SCHEMBL20520 0.99 MEN1 (1.00) MEN1KMT2AMAPTBLMKDM4E
Homidium SCHEMBL1879927 0.99 MEN1 (0.97) MEN1KMT2AMAPTBLMKDM4E
Homidium SCHEMBL19690770 0.99 MEN1 (0.97) MEN1KMT2AMAPTBLMKDM4E
Homidium SCHEMBL7751164 0.99 MEN1 (1.00) MEN1KMT2AMAPTBLMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023101463-A1 ALGICIDAL COMPOSITION CONTAINING 1-(1-HALOVINYL)ARENE COMPOUND 한국화학연구원 2023-06-08 WO claimed
US-20250289876-A1 CONNEXIN 43 ANTIBODIES AND USE THEREOF ALAMAB THERAPEUTICS INC (US) 2025-09-18 US disclosed
US-20250230233-A1 CONNEXIN 43 ANTIBODIES AND USE THEREOF ALAMAB THERAPEUTICS INC (US) 2025-07-17 US disclosed
CN-114621346-B Compositions and methods for targeting connexin hemichannels 德克萨斯州大学系统董事会 2025-06-10 CN disclosed
EP-3952912-B1 CELL-PENETRATING CONJUGATE SYSTEMS UNIV DANMARKS TEKNISKE (DK) 2025-04-23 EP disclosed
CN-119700967-A Connexin 43 antibodies and uses thereof 阿拉玛布治疗学股份有限公司 2025-03-28 CN disclosed
US-20250059272-A1 Compositions and Methods for Targeting Connexin Hemichannels BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2025-02-20 US disclosed
US-12227561-B2 Connexin 43 antibodies and use thereof ALAMAB THERAPEUTICS, INC. (US) 2025-02-18 US disclosed
CN-112384244-B Connexin 43 antibodies and uses thereof 阿拉玛布治疗学股份有限公司 2025-01-24 CN disclosed
US-12187794-B2 Connexin 43 antibodies and use thereof ALAMAB THERAPEUTICS, INC. (US) 2025-01-07 US disclosed
US-20230210994-A1 CELL-PENETRATING CONJUGATE SYSTEMS DANMARKS TEKNISKE UNIVERSITET (DK) 2023-07-06 US disclosed
WO-2023101463-A1 ALGICIDAL COMPOSITION CONTAINING 1-(1-HALOVINYL)ARENE COMPOUND 한국화학연구원 2023-06-08 WO disclosed
US-11596639-B2 Substituted indole Mcl-1 inhibitors VANDERBILT UNIVERSITY (US) 2023-03-07 US disclosed
CN-115551839-A Heteroaryl-triazole compounds as pesticides 拜耳公司 2022-12-30 CN disclosed
US-20220411494-A1 CONNEXIN 43 ANTIBODIES AND USE THEREOF ALAMAB THERAPEUTICS, INC. (US) 2022-12-29 US disclosed
CN-111246741-B Active ingredient combinations having insecticidal/acaricidal properties 拜耳公司 2022-08-02 CN disclosed
CN-114621346-A Compositions and methods for targeting connexin hemichannels 德克萨斯州大学系统董事会 2022-06-14 CN disclosed
US-20220169721-A1 Compositions and Methods for Targeting Connexin Hemichannels BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2022-06-02 US disclosed
US-20220080027-A1 METHODS OF TREATING NEURODEGENERATIVE DISEASES BY TARGETING THE PURINERGIC AND/OR ADENOSINE RECEPTORS UNIVERSITY OF NORTH DAKOTA 2022-03-17 US disclosed
EP-3952912-A1 CELL-PENETRATING CONJUGATE SYSTEMS Danmarks Tekniske Universitet (DK) 2022-02-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210994-A1 CELL-PENETRATING CONJUGATE SYSTEMS SLC2A3, SLC2A1, SLC2A2 MEN1 277/4885KMT2A 3505/4885MAPT 2405/4885
US-11596639-B2 Substituted indole Mcl-1 inhibitors MCL1, BCL2L1, BCL9 MEN1 3549/4885KMT2A 824/4885MAPT 2996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.